B5-05: Frameless stereotactic body radiotherapy using four dimensional cone beam CT guidance Jan-Jakob Sonke, Jose Belderbos, Maddalena Rossi, Jochem.

Slides:

Advertisements

Similar presentations

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Advertisements

ICRU 50 & ICRU 62 Paweł Kukołowicz Holycross Cancer Centre

Carmel McDerby Clatterbridge Centre for Oncology, Merseyside,UK

Dr. Malhar Patel DNB (Radiation Oncology)

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Jeffrey Bradley, MD Journal of Thoracic Oncology

Image–Guided Radiation Therapy for Non–small Cell Lung Cancer

Introduction and Objectives

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting Danielle Rodin, MD, Surbhi Grover, MD, MPH, Melody J. Xu, MD,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Image–Guided Radiation Therapy for Non–small Cell Lung Cancer

Required target margins for image-guided lung SBRT: Assessment of target position intrafraction and correction residuals Chirag Shah, MD, Larry L. Kestin,

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report Lore Helene Braun, Stefan.

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Practical Assessment of Bronchoscopically Inserted Fiducial Markers for Image Guidance in Stereotactic Lung Radiotherapy Price Jackson, PhD, Daniel P.

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Cone beam computed tomography-based monitoring and management of target and organ motion during external beam radiotherapy in cervical cancer Nina Boje.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Technical Advances of Radiation Therapy for Thymic Malignancies

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Angjelina Protik, Marcel van Herk, Marnix Witte, Jan-Jakob Sonke

Cone-Beam CT-based position verification for oesophageal cancer: Evaluation of registration methods and anatomical changes during radiotherapy A. van.

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Journal of Thoracic Oncology

PD5-1-7: Time trends in nodal CT volume and nodal motion during radiotherapy for patients with stage III non-small cell lung cancer Geert Bosmans, Angela.

Proton SBRT for Medically Inoperable Stage I NSCLC

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy Philippe Giraud, MD, PhD, Esra Morvan, PhD, Line Claude, MD, Françoise Mornex,

MTP13-01: Indications and limitations of bronchoscopy

Jeffrey Bradley, MD Journal of Thoracic Oncology

Iris Metastasis from Small-Cell Lung Cancer

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis A.

IASLC 6th Latin American Conference on Lung Cancer

PD6-1-6: Mid-course resimulation for small cell lung cancer patients receiving definitive chemoradiation: sparing of normal lung and esophagus without.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography.

Journal of Thoracic Oncology

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

David Garfield, MD Journal of Thoracic Oncology

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Stereotactic Body Radiotherapy for Central Lung Tumors

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

B5-05: Frameless stereotactic body radiotherapy using four dimensional cone beam CT guidance Jan-Jakob Sonke, Jose Belderbos, Maddalena Rossi, Jochem Wolthaus, Eugene Damen, Jacobus A. Burgers, Joos Lebesque, Marcel Van Herk Journal of Thoracic Oncology Volume 2, Issue 8, Pages S348-S349 (August 2007) DOI: 10.1097/01.JTO.0000283171.04105.8a Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 a) Coronal slices of three frames of a 4D-CBCT scan acquired just prior to SBRT treatment. Despite some artifacts, tumor motion and accurate alignment can be easily verified. b) Cranial-caudal GTV-to-PTV margin (no CTV margin used) required to account for delineation uncertainties, breathing motion, residual setup error and intrafraction variability as a function of tumor peak-to-peak amplitude: using 4D-CBCT guidance compared to a bony anatomy driven protocol combined with an ITV approach. Even at large tumor amplitudes margins are relatively small due to accurate guidance, shallow penumbra in lung and dose prescription to relative low iso-doses (typically 70% to 80%). Journal of Thoracic Oncology 2007 2, S348-S349DOI: (10.1097/01.JTO.0000283171.04105.8a) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions